All In Biotech

Drug Trial Radar · NCT06453213

Open-label Study of Cenobamate Monotherapy in Adult Subjects With Newly Diagnosed or Recurrent Partial-Onset Epilepsy

Last checked: Nov 20, 2026Latest source record: Oct 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

49

Actual

Start

Oct 14, 2024

Primary completion

May 26, 2027

Study completion Jul 9, 2027

Sponsor

Lead sponsor
SK Life Science, Inc.Industry
Sponsor type
Industry
First posted
Jun 11, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 74 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Cenobamate (YKP3089) is a small molecule approved in the United States (US), Europe and several other countries around the world for the treatment of Partial-Onset (focal) seizures in adult subjects (≥18 years of age). In the US it is approved for use as monotherapy, however, there is little clinical data assessing its use as monotherapy in adults with POS. This study is designed to explore the effectiveness of doses of 100 mg/day and 200 mg/day as monotherapy in adult subjects with newly diagnosed or recurrent POS/focal onset epilepsy.

Conditions

  • Focal Onset Seizure

Interventions

  • CenobamateDrug

    The 100 mg/ day Treatment Period includes a 6-week Titration Phase and a 26-week Maintenance Phase. During the Titration Phase subjects will be treated with cenobamate 12.5 mg/day for two weeks, 25 mg/day for two weeks and 50 mg/day for two weeks. Subjects tolerating cenobamate at the end of the Titration Phase will continue treatment with 100 mg/day in the Maintenance Phase for 26 weeks. If the subject does not experience a certain type of seizure in the 100 mg/day Maintenance Phase, he/she can enter the Optional Extension Period (100 mg/day). The 200 mg/day treatment period consists of a 2-week Titration Phase and a 26-week Maintenance Phase. During the 2-week Titration Phase, subjects will receive cenobamate 150 mg/day before entering the 26-week 200 mg/day Maintenance Phase. If the subject does not experience a certain type of seizure during the 200 mg/day Maintenance Phase, he/she can enter the 26 week Optional Extension Period (200 mg/day).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Seizure-freedom during the 26-week Maintenance Phase of the 100 mg/day Treatment PeriodTime frame: 32 weeks

Locations

19 sites in 1 country. Site status is shown where the registry gives one.

  • Arizona Neuroscience Research

    Phoenix, Arizona

  • Center For Neurosciences

    Tucson, Arizona

  • Clinical Trials Inc

    Little Rock, Arkansas

  • Neuro Pain Medical Center

    Fresno, California

  • Hoag Physician Partners

    Newport Beach, California

  • Hartford Hospital

    Hartford, Connecticut

  • Yale School of Medicine - Yale-New Haven Hospital

    New Haven, Connecticut

  • Elite Clinical Research

    Miami, Florida

  • Knight Neurology

    Rockledge, Florida

  • Consultants In Epilepsy and Neurology

    Boise, Idaho

  • Bluegrass Epilepsy Research LLC

    Lexington, Kentucky

  • Louisiana State University Health Sciences

    Shreveport, Louisiana

  • John Hopkins Epilepsy Center

    Baltimore, Maryland

  • Henry Ford Health System

    Detroit, Michigan

  • Wayne Neurology PLC

    Plymouth, Michigan

  • University of Missouri Health Care

    Columbia, Missouri

  • NY Neurology Associates

    New York, New York

  • Mount Sinai Hospital

    New York, New York

  • DHR Health Institute for Research and Development

    Edinburg, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.